Pharnext (France) Today
| ALPHA Stock | EUR 0.0002 0.00 0.00% |
Performance0 of 100
| Odds Of DistressOver 86
|
Pharnext is selling at 2.0E-4 as of the 26th of December 2024; that is No Change since the beginning of the trading day. The stock's last reported lowest price was 1.0E-4. Pharnext has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 26th of November 2024 and ending today, the 26th of December 2024. Click here to learn more.
Pharnext SA, a clinical-stage biopharmaceutical company, develops therapeutics for severe orphan and common neurodegenerative diseases in France. The company was founded in 2007 and is based in Issy-Les-Moulineaux, France. Pharnext S is traded on Paris Stock Exchange in France. The company has 875.25 M outstanding shares. More on Pharnext SA
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Pharnext Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Pharnext's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Pharnext or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Pharnext SA (ALPHA) is traded on Euronext Paris in France and employs 28 people. The company currently falls under 'Nano-Cap' category with a current market capitalization of 680.75 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Pharnext's market, we take the total number of its shares issued and multiply it by Pharnext's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Pharnext SA operates under Healthcare sector and is part of Biotechnology industry. The entity has 875.25 M outstanding shares.
Pharnext SA has accumulated about 18.17 M in cash with (23.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.51, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Pharnext Probability Of Bankruptcy
Ownership AllocationPharnext owns a total of 875.25 Million outstanding shares. Roughly 99.28 pct. of Pharnext outstanding shares are held by general public with 0.68 % owned by insiders and only 0.04 (%) by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Pharnext Ownership Details
Pharnext Stock Against Markets
| ALPHA | 0.00 |
|
| Competition | Refresh |
Be your own money manager
Our tools can tell you how much better you can do entering a position in Pharnext without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run ETFs Now
ETFsFind actively traded Exchange Traded Funds (ETF) from around the world |
| All Next | Launch Module |
Pharnext Corporate Management
Elected by the shareholders, the Pharnext's board of directors comprises two types of representatives: Pharnext inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pharnext. The board's role is to monitor Pharnext's management team and ensure that shareholders' interests are well served. Pharnext's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pharnext's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joshua Schafer | Interim Chairman | Profile | |
| Xavier MSc | Chief Officer | Profile | |
| Rodolphe Hajj | Chief Officer | Profile | |
| Susanne Dorn | Chief Officer | Profile | |
| Daniel Cohen | Director | Profile | |
| DSc Chumakov | Chairman CoFounder | Profile | |
| Rob Quinn | Chief Officer | Profile |
Additional Tools for Pharnext Stock Analysis
When running Pharnext's price analysis, check to measure Pharnext's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharnext is operating at the current time. Most of Pharnext's value examination focuses on studying past and present price action to predict the probability of Pharnext's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharnext's price. Additionally, you may evaluate how the addition of Pharnext to your portfolios can decrease your overall portfolio volatility.